

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |  |
|---|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br>C07K 14/18, 19/00, A61K 39/29   | <b>A1</b> | <b>(11) International Publication Number:</b> WO 97/43310<br><b>(43) International Publication Date:</b> 20 November 1997 (20.11.97)   |
| <b>(21) International Application Number:</b> PCT/US97/07632<br><b>(22) International Filing Date:</b> 8 May 1997 (08.05.97)<br><b>(30) Priority Data:</b><br>08/644,544 10 May 1996 (10.05.96) US<br><b>(71) Applicant:</b> SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).<br><b>(72) Inventors:</b> ZHANG, Rumin; 4 Devon Road, Edison, NJ 08820 (US). MUI, Philip, W.; 1 Windswept Lane, Freehold, NJ 07728 (US). WEBER, Patricia, C.; 1970 Timber Lakes Drive, Yardley, PA 19067 (US).<br><b>(74) Agents:</b> DULAK, Norman, C. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). |           | <b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.<br/>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| <b>(54) Title:</b> SYNTHETIC INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE<br><br><b>(57) Abstract</b><br><p>An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the NS4A cofactor. In another embodiment the inhibitor is a bivalent inhibitor comprised of a subsequence, a mutated subsequence or a mutated full-length of a substrate of the NS3 protease linked to a subsequence, a mutated subsequence or a mutated full-length subsequence of the HCV NS4A cofactor.</p>          |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

## SYNTHETIC INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

5

### BACKGROUND OF THE INVENTION

10           Hepatitis C virus (HCV) is considered to be the major etiological agent of non-A non-B (NANB) hepatitis, chronic liver disease, and hepatocellular carcinoma (HCC) around the world. The viral infection accounts for greater than 90% of transfusion -associated hepatitis in U.S. and it is the predominant form of hepatitis in adults over 40 years of age. Almost all of the infections result in chronic hepatitis and nearly 20% develop liver cirrhosis.

          The virus particle has not been identified due to the lack of an efficient *in vitro* replication system and the extremely low amount of HCV particles in infected liver tissues or blood. However, molecular cloning of the viral genome has been accomplished by isolating the messenger RNA (mRNA) from the serum of infected chimpanzees then cloned using recombinant methodologies. [Grakoui A. *et al.* J. Virol. 67: 1385 - 1395 (1993)] It is now known that HCV contains a positive strand RNA genome comprising approximately 9400 nucleotides, whose organization is similar to that of flaviviruses and pestiviruses. The genome of HCV, like that of flavi- and pestiviruses, encodes a single large polyprotein of about 3000 amino acids which undergoes proteolysis to form mature viral proteins in infected cells.

30

          Cell-free translation of the viral polyprotein and cell culture expression studies have established that the HCV polyprotein is processed by cellular and viral proteases to produce the putative structural and nonstructural (NS) proteins. At least nine mature viral proteins are produced from the polyprotein by specific proteolysis. The order and nomenclature of the cleavage products are as follows: NH<sub>2</sub>-C-E1-E2-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH. The three amino terminal putative structural proteins, C (capsid), E1, and E2 (two

35

- 2 -

envelope glycoproteins), are believed to be cleaved by host signal peptidases of the endoplasmic reticulum(ER) . The host enzyme is also responsible for generating the amino terminus of NS2 . The proteolytic processing of the nonstructural proteins are carried out by the viral proteases: NS2-3 and NS3, contained within the viral polyprotein. The NS2-3 protease catalyzes the cleavage between NS2 and NS3. It is a metalloprotease and requires both NS2 and the protease domain of NS3. The NS3 protease catalyzes the rest of the cleavages of the substrates in the nonstructural part of the polyprotein. The NS3 protein contains 631 amino acid residues and is comprised of two enzymatic domains: the protease domain contained within amino acid residues 1-181 and a helicase ATPase domain contained within the rest of the protein. It is not known if the 70 kD NS3 protein is cleaved further in infected cells to separate the protease domain from the helicase domain, however, no cleavage has been observed in cell culture expression studies.

The NS3 protease is a member of the serine proteinase class of enzymes. It contains His, Asp, and Ser as the catalytic triad. Mutation of the catalytic triad residues abolishes the cleavages at substrates NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B. The cleavage between NS3 and NS4A is mediated through an intramolecular enzymatic reaction, whereas the cleavages at NS4A/4B, 4B/5A, 5A/5B sites occur in a *trans* enzymatic reaction.

Experiments using transient expression of various forms of HCV NS polyproteins in mammalian cells have established that the NS3 serine protease is necessary but not sufficient for efficient processing of all these cleavages. Like flaviviruses, the HCV NS3 protease also requires a cofactor to catalyze some of these cleavage reactions. In addition to the serine protease NS3, the NS4A protein is absolutely required for the cleavage of the substrate at the NS3/4A and 4B/5A sites and increases the efficiency of cleavage of the substrate between 5A/5B, and possibly 4A/4B.

Because the HCV NS3 protease cleaves the non-structural HCV proteins which are necessary for the HCV replication, the NS3 protease can be a target for the development of therapeutic agents against the

- 3 -

HCV virus. Thus there is a need for the development of inhibitors of the HCV protease.

### SUMMARY OF THE INVENTION

5

The present invention fills this need by providing for a bivalent inhibitor of an hepatitis C NS3 protease comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide.

15

The present application further provides for an inhibitor of an HCV protease comprised of a peptide, said peptide being a subsequence, a mutated subsequence, or a mutated full-length sequence of a substrate of the HCV NS3 protease.

20

The present application further provides for an inhibitor of an HCV NS3 protease comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of an HCV NS4A polypeptide.

25

The present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide.

30

The present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor being comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.

35

- 4 -

The present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor  
5 being comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of an HCV NS4A polypeptide.

The present invention further comprises a pharmaceutical  
10 composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being an inhibitor of an HCV NS3 protease, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated  
15 subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide, and a pharmaceutical carrier.

The present invention further provides for a pharmaceutical  
20 composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, said inhibitor being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.

25

The present invention further provides for a pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, wherein said inhibitor  
30 is comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length subsequence of an HCV NS4A polypeptide.

35

- 5 -

### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 schematically depicts an embodiment of a bivalent inhibitor of the present invention.

5

Figure 2 depicts the recombinant synthesis of plasmid pBJ1015.

Figure 3 depicts the recombinant synthesis of plasmid pTS56-9.

10 Figure 4 depicts the recombinant synthesis of plasmid pJB1006.

Figure 5 depicts the recombinant synthesis of plasmid pBJ1022.

15 Figure 6 depicts the recombinant synthesis of plasmid pNB(-V)182Δ4AHT.

Figure 7 depicts the recombinant synthesis of plasmid pT5His/HIV/183.

### DETAILED DESCRIPTION OF THE INVENTION

20

The teachings of all references cited are incorporated herein in their entirety by reference.

25 The present invention are inhibitors of the HCV NS3 protease. The present invention relates to inhibitors of the HCV NS3 protease which inhibit either the interaction of a substrate or cofactor NS4A with the NS3 protease or a bivalent inhibitor which inhibits the interaction of the NS3 protease with both cofactor NS4A and a substrate of the NS3 protease. Compared to inhibitors targeting only at a single binding site,  
30 bivalent enzyme inhibitors may provide additional advantages in terms of higher binding affinity (potency), as well as enhanced specificity against similar cellular host enzymes for reduced toxicity effects.

#### Design Strategy of Bivalent Inhibitors of HCV NS3 Protease

35

The basic strategy for the design of bivalent inhibitors of HCV NS3 protease involved the devise of a molecular framework consisting of three individual components:

- 6 -

1. a region appropriate for binding to a substrate binding site;
  2. a region suitable for binding to the NS4A binding site;
  3. a flexible linker region connecting regions (1) and (2) which
- 5 would allow the two end regions to bind to their respective binding sites.

Schematically, this is represented by Figure 1 in which the substrate subsequence is depicted as block, 10, being attached to linker 12, and said linker 12 being attached to the polypeptide NS4A designated 14.

Since the NS3 protease cleaves the HCV polyprotein at the NS3/4A, 4A/4B, 4B/5A and 5A/5B junctions, then subsequences of or mutated subsequences of these sites can be used as substrate inhibitors.

15 A substrate inhibitor which is a subsequence of the inhibitor should be a subsequence which is prior to or after the cleavage site but preferably should not contain the cleavage site. A mutated subsequence or mutated full-length sequence of the substrate can be used if the cleavage site is mutated so that the cleavage of the substrate does not occur cleavage

20 leads to mechanism-based inactivation of the protease.

For example, the NS3/4A cleavage site contains the following sequence:

|    |     |     |     |     |     |                   |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Cys | Met | Ser | Ala | Asp | Leu               | Glu | Val | Val | Thr | Ser | Thr | Trp | Val | Leu |
| 25 |     |     |     |     |     | 5                 |     |     |     | 10  |     |     |     | 15  |     |
|    | Val | Gly | Gly | Val | Leu | (SEQ. ID NO.: 26) |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     | 20  |                   |     |     |     |     |     |     |     |     |     |

The cleavage site is between the threonine at position 10 and the serine at position 11. Any subsequence inhibitor should preferably be before the serine or after the threonine residue. Alternatively, a mutated subsequence or sequence can be produced by changing the threonine/serine cleavage site at position 10-11 to eliminate the cleavage site.

35



- 7 -

NS4A/4B contains the following sequence.

```

Tyr Gln Glu Phe Asp Glu Met Glu Glu Cys Ser Gln His Leu Pro
                    5                      10                15
5   Tyr Ile Glu Gln Gly (SEQ ID NO.: 27).
                    20

```

10 The cleavage site is between the cysteine residue at position 10 and the serine at position 11. Any subsequence should preferably be before the serine or after the cysteine, but should preferably not contain both the cysteine and the serine. Alternatively, a mutated subsequence or sequence can be produced by changing the cysteine/serine cleavage site at position 10 - 11 to eliminate the cleavage site.

15 NS4B/5A contains the following sequence.

```

Trp Ile Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu
                    5                      10                15
20 Arg Asp Ile Trp Asp (SEQ ID NO.: 28)
                    20

```

25 The cleavage site is between the cysteine at position 10 and serine at position 11. Any subsequence should preferably end before the serine or start after the cysteine but should preferably not contain both the serine and the cysteine. Alternatively, a mutated subsequence or sequence can be produced by changing the cysteine/serine cleavage sit at position 10 - 11 to eliminate the cleavage site.

NS5A/5B contains the following sequence.

```

30 Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Thr Trp Thr
                    5                      10                15
    Gly (SEQ. ID NO.: 25)

```

35 The cleavage site is between the cysteine at position 8 and the serine at position 9. Any subsequence should preferably end at the cysteine or start at the serine, but should preferably not contain both the cysteine and the serine. Alternatively, a mutated sequence or subsequence can be

- 8 -

produced by changing the cysteine/serine cleavage site at position 8 - 9 to eliminate the cleavage site.

5           Linker 12 can be any chemical entity that can form a bond with polypeptides 10 and 14. Preferably the linker should be equivalent in length to a carbon chain having about 7-14 carbon residues. Examples of suitable linkers are two 6-aminocaproic acid (Acp) residues or an Acp and Lys wherein one of the polypeptides 10 or 14 form a peptide bond  
10       with the  $\epsilon$  amine of lysine.

Examples of bivalent inhibitors of the present invention are the following:

15           Glu-Asp-Val-Val-Cys-Cys-Acp-Acp-Cys-Val-Val-Ile-Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO: 1)

            Glu-Asp-Val-Val-Cys-Cys-Acp-Cys-Val-Val-Ile-Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys-Lys (SEQ ID NO:2)  
20

            Glu-Asp-Val-Val-Cys-Cys-Acp-Xaa-Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO: 3)

            wherein Xaa is a lysine residue having a peptide bond between its  
25        $\epsilon$ -amino and the carboxyl group of the following lysine which forms a peptide bond with the glycine at position 10. Furthermore, the glutamic acid residue at position 1 may or may not be acetylated.

30           Glu-Asp-Val-Val-Cys-Cys-Xaa-Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO: 4)

            wherein Xaa is Lysine having a peptide bond between its  $\epsilon$ -amino and the carboxyl group of the following lysine which forms a peptide bond with the Gly; furthermore, the carboxyl group of the Xaa forms a  
35       peptide bond with the  $\alpha$ -amino group of another lysine (not shown);

            Glu-Asp-Val-Val-Cys-Cys-Acp-Acp-Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO: 5)

- 9 -

wherein the amino acids at positions 9-21 are preferably D-amino acids;

5       Glu-Asp-Val-Val-Cys-Cys-Acp-Lys-Cys-Val-Val-Ile-  
Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO: 6)

10       wherein the lysine residue at position 8 has a peptide bond  
between the carboxyl of Acp and the  $\alpha$  amino group of the lysine, and  
the  $\epsilon$  amino group of the lysine at position 8 forms a peptide bond with  
the carboxyl group of the cysteine residue at position 9 and the amino  
acid residues at positions 9-21 are preferably D-amino acid residues;

15       Glu-Asp-Val-Val-Cys-Cys-Acp-Lys-Gly-Ser-Leu-Val-Ile-Arg-  
Gly-Val-Ile-Val-Val-Cys-Lys (SEQ ID NO: 7)

wherein amino acid residues at positions 8-20 are preferably D-amino acid residues;

20       Glu-Asp-Val-Val-Cys-Cys-Xaa-Cys-Val-Val-Ile-Val-Gly-  
Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO: 8)

25       wherein Xaa is a Lys which forms a peptide bond between its  $\epsilon$ -  
amino acid and the carboxyl group of the Cys residue at position 8 and  
the carboxyl group of the Lys residue forms a peptide bond with an alpha  
amino group of another Lys residue (not shown), preferably the amino  
acid residues at positions 8 - 20 are D- amino acids.

30       Examples of suitable monovalent inhibitors of the present  
invention are the following:

Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys-Lys  
(SEQ ID NO.: 9)

35       wherein the amino acid residues at positions 1- 13 are preferably  
D-amino acid residues;

Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Lys (SEQ ID NO.: 10)

wherein amino acid residues at positions 1 - 11 are preferably  
D-amino acid residues;

- 10 -

Cys-Val-Val-Ile-Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys  
(SEQ ID NO.: 11)

5 wherein the amino acid residues are preferably D-amino acid residues;

Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val (SEQ ID NO.: 12)

10 wherein the amino acid residues are preferably D-amino acid residues and the serine residue at position 1 has been preferably acetylated;

Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys  
(SEQ ID NO.: 13)

15 wherein the amino acid residues are preferably D-amino acid residues the lysine residue at position 1 is preferably acetylated;

Xaa-Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile Val-Val-Cys-Lys-Lys  
(SEQ ID NO.: 14);

20 wherein Xaa is biotin and the amino acid residues at positions 2 - 14 are preferably D-amino acid residues;

Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys-Xaa-Lys  
(SEQ ID NO.: 15);

25 Xaa is a lysine residue in which the  $\epsilon$  amino group of the lysine forms a peptide bond with a biotin, and amino acid residues at positions 1 - 13 are preferably D-amino acid residues.

30

The inhibitors of the present invention can be synthesized by a suitable method such as by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis.  
35 The polypeptides are preferably prepared by solid phase peptide synthesis as described by Merrifield, J. Am. Chem. Soc. 85:2149 (1963). The synthesis is carried out with amino acids that are protected at the alpha-amino terminus. Trifunctional amino acids with labile side-

- 11 -

chains are also protected with suitable groups to prevent undesired chemical reactions from occurring during the assembly of the polypeptides. The alpha-amino protecting group is selectively removed to allow subsequent reaction to take place at the amino-terminus. The  
5 conditions for the removal of the alpha-amino protecting group do not remove the side-chain protecting groups.

The alpha-amino protecting groups are those known to be useful in the art of stepwise polypeptide synthesis. Included are  
10 acyl type protecting groups (*e.g.*, formyl, trifluoroacetyl, acetyl), aryl type protecting groups (*e.g.*, biotinyl), aromatic urethane type protecting groups [*e.g.*, benzyloxycarbonyl (Cbz), substituted benzyloxycarbonyl and 9-fluorenylmethyloxy-carbonyl (Fmoc)],  
15 aliphatic urethane protecting groups [*e.g.*, t-butyloxycarbonyl (tBoc), isopropylloxycarbonyl, cyclohexylloxycarbonyl] and alkyl type protecting groups (*e.g.*, benzyl, triphenylmethyl). The preferred protecting groups are tBoc and Fmoc, thus the peptides are said to be synthesized by tBoc and Fmoc chemistry, respectively.

20 The side-chain protecting groups selected must remain intact during coupling and not be removed during the deprotection of the amino-terminus protecting group or during coupling conditions. The side-chain protecting groups must also be removable upon the completion of synthesis, using reaction  
25 conditions that will not alter the finished polypeptide. In tBoc chemistry, the side-chain protecting groups for trifunctional amino acids are mostly benzyl based. In Fmoc chemistry, they are mostly tert.-butyl or trityl based.

30 In tBoc chemistry, the preferred side-chain protecting groups are tosyl for Arg, cyclohexyl for Asp, 4-methylbenzyl (and acetamidomethyl) for Cys, benzyl for Glu, Ser and Thr, benzyloxymethyl (and dinitrophenyl) for His, 2-Cl-benzyloxycarbonyl for Lys, formyl for Trp and 2-bromobenzyl for Tyr. In Fmoc  
35 chemistry, the preferred side-chain protecting groups are 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) or 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg, trityl for

- 12 -

Asn, Cys, Gln and His, tert-butyl for Asp, Glu, Ser, Thr and Tyr, tBoc for Lys and Trp.

5 Solid phase synthesis is usually carried out from the carboxyl-terminus by coupling the alpha-amino protected (side-chain protected) amino acid to a suitable solid support. An ester linkage is formed when the attachment is made to a chloromethyl, chlorotriyl or hydroxymethyl resin, and the resulting polypeptide will have a  
10 free carboxyl group at the C-terminus. Alternatively, when an amide resin such as benzhydrylamine or p-methylbenzhydrylamine resin (for tBoc chemistry) and Rink amide or PAL resin (for Fmoc chemistry) is used, an amide bond is formed and the resulting polypeptide will have a carboxamide group at the C-terminus. These  
15 resins, whether polystyrene- or polyamide-based or polyethyleneglycol-grafted, with or without a handle or linker, with or without the first amino acid attached, are commercially available, and their preparations have been described by Stewart et al (1984), "Solid Phase Peptide Synthesis" (2nd Edition), Pierce Chemical Co.,  
20 Rockford, IL.; and Bayer & Rapp (1986) *Chem. Pept. Prot.* 3, 3; and Atherton, et al. (1989) *Solid Phase Peptide Synthesis: A Practical Approach*, IRL Press, Oxford.

The C-terminal amino acid, protected at the side-chain if  
25 necessary and at the alpha-amino group, is attached to a hydroxymethyl resin using various activating agents including dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIPCDI) and carbonyldiimidazole (CDI). It can be attached to chloromethyl or chlorotriyl resin directly in its cesium  
30 tetramethylammonium salt form or in the presence of triethylamine (TEA) or diisopropylethylamine (DIEA). First amino acid attachment to an amide resin is the same as amide bond formation during coupling reactions

35 Following the attachment to the resin support, the alpha-amino protecting group is removed using various reagents depending on the protecting chemistry (e.g., tBoc, Fmoc). The extent of Fmoc removal can be monitored at 300-320 nm or by a

- 13 -

conductivity cell. After removal of the alpha-amino protecting group, the remaining protected amino acids are coupled stepwise in the required order to obtain the desired sequence.

5 Various activating agents can be used for the coupling reactions including DCC, DIPCDI, 2-chloro-1,3-dimethylimidium hexafluorophosphate (CIP), benzotriazol-1-yl-oxy-tris- (dimethylamino)-phosphonium hexafluorophosphate (BOP) and its  
10 pyrrolidine analog (PyBOP), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP), N- [(1H-benzotriazol-1-yl) - (dimethylamino) methylene] -N-methylmethanaminium hexafluorophosphate N-oxide (HBTU) and its tetrafluoroborate  
15 analog (TBTU) or its pyrrolidine analog (HBPyU), (HATU) and its tetrafluoroborate analog (TATU) or pyrrolidine analog (HAPyU). The most common catalytic additives used in coupling reactions include  
20 4-dimethylaminopyridine (DMAP), 3-hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (HODhbt), N-hydroxybenzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt). Amino acid fluorides or chlorides may be used for difficult couplings. Each protected amino  
25 acid is used in excess (>2.0 equivalents), and the couplings are usually carried out in N-methylpyrrolidone (NMP) or in DMF, CH<sub>2</sub>Cl<sub>2</sub> or mixtures thereof. The extent of completion of the coupling reaction can be monitored at each stage, *e.g.*, by the ninhydrin reaction as described by Kaiser *et al.*, *Anal. Biochem.* 34:595 (1970). In cases  
30 where incomplete coupling is found, the coupling reaction is extended and repeated and may have chaotropic salts added. The coupling reactions can be performed automatically with commercially available instruments such as ABI model 430A, 431A and 433A peptide synthesizers.

30 After the entire assembly of the desired peptide, the peptide-resin is cleaved with a reagent with proper scavengers. The Fmoc peptides are usually cleaved and deprotected by TFA with scavengers (*e.g.*, H<sub>2</sub>O, ethanedithiol, phenol and thioanisole). The tBoc peptides  
35 are usually cleaved and deprotected with liquid HF for 1-2 hours at -5 to 0°C, which cleaves the polypeptide from the resin and removes most of the side-chain protecting groups. Scavengers such as anisole, dimethylsulfide and p-thiocresol are usually used with the liquid HF

- 14 -

to prevent cations formed during the cleavage from alkylating and acylating the amino acid residues present in the polypeptide. The formyl group of Trp and dinitrophenyl group of His need to be removed, respectively, by piperidine and thiophenol in DMF prior to the HF cleavage. The acetamidomethyl group of Cys can be removed by mercury(II) acetate and alternatively by iodine, thallium (III) trifluoroacetate or silver tetrafluoroborate which simultaneously oxidize cysteine to cystine. Other strong acids used for tBoc peptide cleavage and deprotection include trifluoromethanesulfonic acid (TFMSA) and trimethylsilyltrifluoroacetate (TMSOTf).

In particular the peptides of the present invention were assembled from a Fmoc-Amide resin or a Fmoc-L-Lys- (tBoc) - Wang resin on an ABI model 433A synthesizer (Applied Biosystems, Foster City, CA) by solid phase peptide synthesis method as originally described by Merrifield, J. Am.Chem.Soc. 85:2149 (1963) but with Fmoc chemistry. The side chains of trifunctional amino acids were protected by tert.-butyl for Glu, Asp and Ser, trityl for Cys, tert.-butoxycarbonyl (tBoc) for Lys and 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) or 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg. N-a-Fmoc protected amino acids were pre-activated by HATU and 1-hydroxy-7-azabenzotriazole (HOAt) prior to coupling to the resin. Dimethylsulfoxide (20%) was added during conditional extended coupling and Fmoc deprotection reactions. The synthesis of the inhibitors SEQ ID NOs: 1, 2, 5, 7, and 9-15 was accomplished by sequential and linear assembly of appropriate D- and L-amino acids and achiral amino acids (Gly and Ahx). The synthesis of the inhibitors SEQ ID NOs: 3, 4, 6, and 8 required orthogonal chain assembly anchored at a Lys residue whose side chain amino group was protected by 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethyl (Dde). For example, for the preparation of the inhibitor SEQ ID NO: 3, Ac-Glu-Asp-Val-Val-Cys-Cys-Acp-Lys-(Amide resin) (SEQ ID NO: 29) was first assembled. Then the Dde protecting group on the Lys residue was removed by 2% hydrazine in dimethylformamide (Bycroft, B.W. et al J. Chem. Soc. Chem. Commun. 1993, 778). Finally the second arm Cys-Val-Val-Ile-Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO:30) was sequentially assembled from the side chain amino group. The assembled peptide was cleaved from the resin with simultaneous



- 15 -

deprotection of side chain protecting groups for three hours by trifluoroacetic acid (TFA) with proper scavengers (80% TFA : 4% phenol : 4% H<sub>2</sub>O, 4% thioanisole : 4% ethanedithiol : 4% triisopropylsilane).

- 5 The cleaved peptide was separated from the resin by filtration and precipitated and repeatedly washed in anhydrous ethyl ether. The precipitated peptide was lyophilized in H<sub>2</sub>O overnight. The lyophilized crude peptide was purified by reverse phase HPLC. The purified peptide was further analyzed by HPLC, mass spectroscopy and amino acid analysis.

10

- One can ascertain if a potential compound is effective as an inhibitor of the HCV NS3 protease by using a high throughput assay utilizing the NS3 protease, the NS4 cofactor and the peptide substrates, either 4B/5A or 5A/5B. These can be used to screen for compounds which inhibit proteolytic activity of the protease. One does this by developing techniques for determining whether or not a compound will inhibit the NS3 protease from cleaving the viral substrates. If the substrates are not cleaved, the virus cannot replicate. One example of such a high throughput assay is the scintillation proximity assay (SPA).
- 20 SPA technology involves the use of beads coated with scintillant. Bound to the beads are acceptor molecules such as antibodies, receptors or enzyme substrates which interact with ligands or enzymes in a reversible manner.

- 25 For a typical SPA based protease assay the substrate peptide is biotinylated at one end and the other end is radiolabelled with low energy emitters such as <sup>125</sup>I or <sup>3</sup>H. The labeled substrate is then incubated with the enzyme. Avidin coated SPA beads are then added which bind to the biotin. When the substrate peptide is cleaved by the protease, the radioactive emitter is no longer in proximity to the scintillant bead and no light emission takes place. Inhibitors of the protease will leave the substrate intact and can be identified by the resulting light emission which takes place in their presence.
- 30

- 35 Another example of a suitable assay technique is an HPLC assay in which the resultant reaction mixture containing the NS3 protease, the substrate products and the potential inhibitor is resolved on an HPLC column to determine the extent of the cleavage of the substrate. If the

- 16 -

substrate has not been cleaved or the cleavage has been inhibited, then only the intact substrate would be present or a reduced amount of the cleaved product will be shown to be present. If this is the case, then the compound is an effective inhibitor of the NS3 protease.

5

#### Pharmaceutical Compositions

The dosage level of inhibitors necessary for effective therapy to inhibit the HCV NS3 protease will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents.

15 Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed.

20 (1990), Mack Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. See also Langer (1990) Science 249:1527-1533.

25 Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. 1 $\mu$ g per kilogram weight of the patient to 500 mg per kilogram weight of the patient with an appropriate carrier is a range from which the dosage can be chosen. Slow release formulations, or a slow release apparatus will often be utilized for continuous

30 administration.

The inhibitors of the HCV NS3 protease of the present invention may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to

35 conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in any conventional dosage formulation. While it is possible for the active ingredient to be administered alone, it is

- 17 -

preferable to present it as a pharmaceutical formulation. Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press, Parrytown, NY; Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn.; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications 2d ed., Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets 2d ed., Dekker, NY; and Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems Dekker, NY. The therapy of this invention may be combined with or used in association with other chemotherapeutic or chemopreventive agents.

The following examples are included to illustrate but not to limit the present invention.

### Example 1

#### Bivalent Inhibitors of HCV NS3 Protease

The bivalent inhibitors of defined by SEQ ID NOs.: 1-10 were synthetically produced as described above and tested for their ability to inhibit the HCV NS3 protease as follows.

Into an aqueous solution containing 25 mM TRIS, 50 mM NaCl, .5 mM EDTA, 10% glycerol and .1% NP40 was placed the potential inhibitor, the HCV NS3 protease at a concentration of 0.05  $\mu$ M - 0.1 mM, the HCV NS4A cofactor at a concentration of 0.05  $\mu$ M - 0.1  $\mu$ M and the 5A/5B substrate at a concentration of 50  $\mu$ M. This solution was then incubated for approximately 2 hours at 30°C after which the solution was applied to an HPLC to determine if the 5A/5B remained intact and

- 18 -

thus the compound was determined to be an inhibitor. However, if the HPLC showed that 5A and 5B were present without the 5A/5B then the compound is not an inhibitor. The potential inhibitors were assayed at several different concentrations to determine the concentration which  
5 produced 50% inhibition of the HCV NS3 protease. The results are shown below.

|    | <u>Inhibitor</u> | <u>IC<sub>50</sub> (μM)</u> |
|----|------------------|-----------------------------|
| 10 | SEQ ID NO:1      | 0.6                         |
|    | 50571-120        |                             |
|    | SEQ ID NO:2      | 3.0                         |
|    | 50962-13         |                             |
| 15 | SEQ ID NO:3      | 3.0                         |
|    | 50828-001        |                             |
|    | SEQ ID NO:4      | 3 - 30                      |
|    | 50962-22         |                             |
| 20 | SEQ ID NO:5      | 0.2                         |
|    | 50571-144        |                             |
|    | SEQ ID NO:6      | 2.0                         |
|    | 50571-150        |                             |
|    | SEQ ID NO:7      | 0.2                         |
|    | 50828-131        |                             |
|    | SEQ ID NO:8      | 0.2                         |
|    | 50962-24         |                             |

- 19 -

Example 2Monovalent Inhibitors of the HCV NS3 Protease

5        Examples of monovalent inhibitors of the HCV NS3 protease are as follows.

|    | Inhibitor      | <u>IC<sub>50</sub>(<math>\mu</math>M)</u> |
|----|----------------|---|
| 10 | SEQ ID NO.: 9  | 0.2                                       |
|    | 50828-129      |   |
|    | SEQ ID NO.: 10 | 5   |
|    | 50962-004      |   |
|    | SEQ ID NO.: 11 | 0.2                                       |
| 15 | 50828-70       |   |
|    | SEQ ID NO.: 12 | 0.6                                       |
|    | 50828-116      |   |
|    | SEQ ID NO.: 13 | 2.0                                       |
|    | 50571-147      |   |
| 20 | SEQ ID NO.: 14 | 0.4                                       |
|    | 50962-047      |   |
|    | SEQ ID NO.: 15 | 0.4                                       |
|    | 50962-050      |   |

25

Examples 3

30

Production of HCV NS3 Protease

A.    Plasmid constructions.

35        Several plasmids were designed and constructed using standard recombinant DNA techniques (Sambrook, Fritsch & Maniatis) to express the HCV protease in *E. coli* (Fig 2-7). All HCV specific sequences originated from the parental plasmid pBRTM/HCV 1-3011 (Grakoui *et*

- 20 -

al.1993). To express the N-terminal 183 amino acid versions of the protease, a stop codon was inserted into the HCV genome using synthetic oligonucleotides (Fig. 3). The plasmids designed to express the N-terminal 246 amino acid residues were generated by the natural NcoI restriction site at the C-terminus.

i) Construction of the plasmid pBJ1015 (Figure 2)

The plasmid pBRTM/HCV 1-3011 containing the entire HCV genome (Grakoui A., *et al.*, *J. Virol.* 67: 1385-1395) was digested with the restriction enzymes Sca I and Hpa I and the 7138 bp (base pair) DNA fragment was isolated and cloned to the Sma I site of pSP72 (Promega) to produce the plasmid, pRJ201. The plasmid pRJ 201 was digested with Msc I and the 2106 bp Msc I fragment was isolated and cloned into the Sma I site of the plasmid pBD7. The resulting plasmid pMBM48 was digested with Kas I and Nco I, and the 734 bp DNA fragment after blunt ending with Klenow polymerase was isolated and cloned into Nco I digested, klenow polymerase treated pTrc HIS B seq expression plasmid (Invitrogen). The ligation regenerated a Nco I site at the 5' end and Nsi I site at the 3' end of HCV sequence. The plasmid pTHB HCV NS3 was then digested with Nco I and Nsi I, and treated with klenow polymerase and T4 DNA polymerase, to produce a blunt ended 738 bp DNA fragment which was isolated and cloned into Asp I cut, klenow polymerase treated expression plasmid pQE30 (HIV). The resulting plasmid pBJ 1015 expresses HCV NS3 (246 amino acids) protease.

(ii) Construction of the plasmid pTS 56-9 with a stop codon after amino acid 183 (Figure 3)

The plasmid pTHB HCV NS3 was digested with Nco I, treated with klenow polymerase, then digested with Bst Y I; and the DNA fragment containing HCV sequence was isolated and cloned into Sma I and Bgl II digested pSP72. The resulting plasmid pTS 49-27 was then digested with Bgl II and Hpa I and ligated with a double stranded oligonucleotide:

GA TCA CCG GTC TAG ATCT

T GGC CAG ATC TAGA (SEQ ID NO 18) to produce pTS 56-9.

Thus, a stop codon was placed directly at the end of DNA encoding the

- 21 -

protease catalytic domain of the NS3 protein. This enabled the HCV protease to be expressed independently from the helicase domain of the NS3 protein.

- 5 (iii) Construction of the plasmid pJB 1006 Fused with a peptide of positively charged amino acids at the carboxy terminus of NS3 183 (Figure 4).

The plasmid pTS 56-9 was digested with Sph I and Bgl II and the DNA  
10 fragment containing HCV sequence was isolated and cloned into a Sph I, Bgl II cut pSP72. The resulting plasmid pJB 1002 digested with Age I and HpaI and ligated to a double stranded oligonucleotide,

CCG GTC CGG AAG AAA AAG AGA CGC TAG C

AG GCC TTC TTT TTC TCT GCG ATC G

- 15 (SEQ ID NO 19), to construct pJB 1006. This fused the hydrophilic, solubilizing motif onto the NS3 protease.

- (iv) Construction of the plasmid pBJ 1022 expressing His-NS3(183)-HT  
20 in *E.coli* (Figure 5)

The plasmid pJB 1006 was digested with NgoM I and Nhe I and the 216 bp DNA fragment was isolated and cloned into Ngo M I, Nhe I cut pBJ 1015 to construct plasmid pBJ 1019. The plasmid pBJ 1019 was digested  
25 with Nar I and Pvu II, and treated with Klenow polymerase to fill in 5' ends of Nar I fragments. The expression plasmid pQE31 (Invitrogen) was digested with BamH I, blunt ended with Klenow polymerase. The 717 bp Nar I- Pvu II DNA fragment was isolated and ligated to the 2787 bp BamH I/Klenowed -Msc I (Bal I) fragment of the expression plasmid  
30 pQE31 (Invitrogen). The recombinant plasmid, pBJ 1022, obtained after transformation into *E.coli* expresses His NS3(2-183)-HT which does not contain any HIV protease cleavage site sequence. The plasmid also contains a large deletion in the CAT (Chloramphenicol Acetyl Transferase) gene.

35

- (v) Construction of the plasmid pNB(-V)182-Δ4A HT (Figure 6)

- 22 -

The plasmid pMBM 48 was digested with Eag I and Xho I, treated with Klenow polymerase and the 320 bp DNA fragment was isolated and cloned into BamH I cut, blunt ended pSP 72 to construct the plasmid pJB1004. The 320 bp fragment encodes 7 amino acid from carboxy terminal of NS3(631), all of NS4A, and the amino terminal 46 amino acid of NS4B. The recombinant plasmid pJB1004 was digested with Eag I and Cel 2, blunt ended with Klenow polymerase. The 220 bp DNA fragment was isolated and cloned into the expression plasmid pQE30 which was digested with BamH I and blunt ended with Klenow polymerase prior to ligation. The resulting plasmid pJB 1011 was digested with NgoM I and Hind III and ligated to a double stranded oligonucleotide ,

CCG GCA .ATT ATA CTT GAC AGG GAG GTT CTC TAC LAG GAA TTC  
15 GT TAA TAT GGA CTG TCC CTC CAA GAG ATG GTC CTT AAG

GAT GAG ATG GAA GAG TGC CCG AAG AAA AAG AGA GGT A  
CTA CTC TAC CTT CTC ACG GCC TGC TTT TGC TCT GGC TTC GA  
(SEQ ID NO 20)

20

to construct the plasmid pNB 4A HT. The plasmid pNB 4AHT was digested with Msl I and Xba I. The 1218 bp DNA fragment was isolated and cloned into Age I cut, klenow polymerase treated, Xba I cut vector DNA of pBJ 1019. The ligation results in a substitution of the 183rd amino acid residue valine by a glycine residue in NS3, and a deletion of amino terminal three amino acid residues of NS4A at the junction. The recombinant plasmid pNB182Δ4A HT comprising NS3(182aa)-G-NS4A(4-54 amino acid) does not contain NS3/NS4A cleavage site sequence at the junction and is not cleaved by the autocatalytic activity of NS3. Finally the plasmid pNB182Δ4A HT (SEQ ID NO 8) was digested with Stu I and Nhe I, the 803 bp DNA fragment was isolated and cloned into Stu I and Nhe I cut plasmid pBJ 1022. The resulting plasmid pNB(-V)182-Δ4A HT contains a deletion of the HIV sequence from the amino terminus end of the NS3 sequence and in the CAT gene (SEQ ID NO 23).

35

(vi) Construction of the plasmid pT5 His HIV-NS3 (Figure 7)



- 23 -

The plasmid pTS56-9 was digested with Bgl II, and treated with Klenow polymerase to fill in 5' ends. The plasmid was then digested with NgoM I and the blunt ended Bgl II/NgoMI fragment containing the NS3 sequence was isolated and ligated to the SglI, Klenow treated NgmMI cut and Sal I klenowed pBJ 1015. The resulting plasmid is designated pT5His HIV 183.

#### Example 4

10

#### Purification of HCV NS3 Protease having a Solubilizing Motif

##### Purification of His182HT (SEQ ID NO 4) and His (-V)182Δ4AHT (SEQ ID NO 8)

15

The recombinant plasmids pBJ1022 and pNB(-V)182Δ4A were used to transform separate cultures of *E. coli* strain M15 [pREP4] (Qiagen), which over-expresses the *lac* repressor, according to methods recommended by the manufacturer. M15 [pREP4] bacteria harboring recombinant plasmids were grown overnight in broth containing 20g/L bactotrypton, 10g/L bacto-yeast extract, 5g/L NaCl (20-10-5 broth) and supplemented with 100μg/ml ampicillin and 25μg/ml kanamycin. Cultures were diluted down to O.D.600 of 0.1, then grown at 30°C to O.D.600 of 0.6 to 0.8, after which IPTG was added to a final concentration of 1mM. At post-induction 2 to 3 hours, the cells were harvested by pelleting, and the cell pellets were washed with 100mM Tris, pH 7.5. Cell lysates were prepared as follows: to each ml equivalent of pelleted fermentation broth was added 50μl sonication buffer (50mM sodium phosphate, pH 7.8, 0.3M NaCl) with 1mg/ml lysozyme; cell suspension was placed on ice for 30 min. Suspension was then brought to a final concentration of 0.2% Tween-20, 10mM dithiothreitol (DTT), and sonicated until cell breakage was complete. Insoluble material was pelleted at 12,000 x g in a microcentrifuge for 15 minutes, the soluble portion was removed to a separate tube and the soluble lysate was then brought to a final concentration of 10% glycerol. Soluble lysates from cells expressing the plasmids produce strongly immunoreactive bands of the predicted molecular weight. Soluble lysates prepared for Ni<sup>2+</sup>

- 24 -

column purification were prepared with 10mM  $\beta$ -mercaptoethanol (BME) instead of DTT. Lysates were stored at  $-80^{\circ}\text{C}$ .

5 Purification using  $\text{Ni}^{2+}$ -Nitrosyl acetic acid (NTA) agarose (QIAGEN)

The proteins were then purified by placing the extracted lysate on an NTA agarose column. NTA agarose column chromatography was used because the histidine tag which was fused to the N-terminus of the proteases readily binds to the nickel column. This produces a powerful affinity chromatographic technique for rapidly purifying the soluble protease. The column chromatography was performed in a batch mode. The  $\text{Ni}^{2+}$  NTA resin (3ml) was washed twice with 50 ml of Buffer A (50mM sodium phosphate pH 7.8 containing 10% glycerol, 0.2% Tween-20, 10mM BME). The lysate obtained from a 250 ml fermentation (12.5 ml) was incubated with the resin for one hour at  $4^{\circ}\text{C}$ . The flow through was collected by centrifugation. The resin was packed into a  $1.0 \times 4$  cm column and washed with buffer A until the baseline was reached. The bound protein was then eluted with a 20 ml gradient of imidazole (0-0.5M) in buffer A. Eluted fractions were evaluated by SDS-PAGE and western blot analysis using a rabbit polyclonal antibody to His-HIV 183.

Purification using POROS metal-chelate affinity column

25 In an alternative method to purify the proteins the lysate containing the proteins were applied to a POROS metal-chelate affinity column. Perfusion chromatography was performed on a POROS MC metal chelate column ( $4.6 \times 50\text{mm}$ , 1.7 ml) precharged with  $\text{Ni}^{2+}$ . The sample was applied at 10 ml/min and the column was washed with buffer A.

30 The column was step eluted with ten column volumes of buffer A containing 25 mM imidazole. The column was further eluted with a 25 column volume gradient of 25-250 mM imidazole in buffer A. All eluted fractions were evaluated by SDS-PAGE and western blot analysis using rabbit polyclonal antibody.

35

Example 5

Peptide Synthesis of the 5A/5B and 4B/5A Substrates

- 25 -

The peptides 5A/5B and 4B/5A substrates (SEQ ID NOs 16, 18, 19, 20 and 21) were synthesized using Fmoc chemistry on an ABI model 431A peptide synthesizer. The manufacture recommended FastMoc™ activation strategy (HBTU/HOBt) was used for the synthesis of 4A  
5 activator peptide. A more powerful activator, HATU with or without the additive HOAt were employed to assemble 5A/5B substrate peptides on a preloaded Wang resin. The peptides were cleaved off the resin and deprotected by standard TFA cleavage protocol. The peptides were  
10 purified on reverse phase HPLC and confirmed by mass spectrometric analysis.

#### Example 6

##### 15 HPLC-assay using a synthetic 5A/5B peptide substrate

To test the proteolytic activity of the HCV NS3 protease the DTEDVVCC SMSYTWGK (SEQ ID NO 16) and soluble HCV NS3 (SEQ ID NO 27) were placed together in an assay buffer. The assay buffer was  
20 50mM sodium phosphate pH 7.8, containing 15% glycerol, 10mM DTT, 0.2% Tween20 and 200 mM NaCl). The protease activity of SEQ ID NO 27 cleaved the substrate into two byproduct peptides, namely 5A and 5B. The substrate and two byproduct peptides were separated on a reversed-phase HPLC column. (Dynamax, 4.6 x 250 mm) with a pore size of 300Å  
25 and a particle size of 5µm. The column was equilibrated with 0.1%TFA (Solvent A) at a flow rate of 1 ml per minute. The substrate and the product peptide standards were applied to the column equilibrated in A. Elution was performed with a acetonitrile gradient (Solvent B=100% acetonitrile in A). Two gradients were used for elution (5% to 70%B in  
30 50 minutes followed by 70% to 100%B in 10 minutes).

- 26 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5       (i) APPLICANT: Schering Corp.

(ii) TITLE OF INVENTION: Synthetic Inhibitors of Hepatitis C Virus  
NS3 Protease

10       (iii) NUMBER OF SEQUENCES: 30

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Schering Corp.

(B) STREET: 2000 Galloping Hill Road

15       (C) CITY: Kenilworth

(D) STATE: New Jersey

(E) COUNTRY: USA

(F) ZIP: 07033-0530

20       (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: Apple Macintosh

(C) OPERATING SYSTEM: Macintosh 7.1

(D) SOFTWARE: Microsoft Word 5.1a

25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

30

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 08/644,544

(B) FILING DATE: 10 May 1996

35       (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Dulak, Norman C.

(B) REGISTRATION NUMBER: 31,608

- 27 -

(C) REFERENCE/DOCKET NUMBER: JB0595

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 908-298-5061

5 (B) TELEFAX: 908-298-5388

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY:

20 Glu Asp Val Val Cys Cys Acp Acp Cys Val Val Ile Val Gly Arg  
5 10 15  
Ile Val Leu Ser Gly Lys  
20

25 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

30 (C) STRANDEDNESS:

(D) TOPOLOGY:

(ii) MOLECULE TYPE: peptide

35 (ix) FEATURE:

(A) NAME/KEY:

- 28 -

Glu Asp Val Val Cys Cys Acp Cys Val Val Ile Val Gly Arg Ile  
5 10 15  
Val Leu Ser Gly Lys Lys  
20

5

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21  
10 (B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY:

## (ii) MOLECULE TYPE: peptide

15

## (ix) FEATURE:

## (A) NAME/KEY:

Glu Asp Val Val Cys Cys Acp Lys Lys Gly Ser Leu Val Ile Arg  
20 5 10 15  
Gly-Val-Ile-Val-Val-Cys  
20

## (2) INFORMATION FOR SEQ ID NO:4:

25

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
30 (D) TOPOLOGY:

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

35

## (A) NAME/KEY:

(B) OTHER INFORMATION: Xaa is lysine having a peptide bond  
between its  $\epsilon$ -amino group and the carboxyl group of lysine at position 8.

- 29 -

The carboxyl group of the Xaa forms a peptide bond with the  $\alpha$ -amino group of another lysine (not shown);

```

      Glu Asp Val Val Cys Cys Xaa Lys Gly Ser Leu Val Ile Arg Gly
5      5      10      15
      Val Ile Val Val Cys
      20

```

(2) INFORMATION FOR SEQ ID NO:5:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

15

(D) TOPOLOGY:

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

20

(A) NAME/KEY:

(B) OTHER INFORMATION: Amino acid residues at positions 9-21 are preferably D-amino acid residues;

```

      Glu Asp Val Val Cys Cys Acp Acp Lys Gly Ser Leu Val Ile Arg
      5      10      15
25     Gly Val Ile Val Val Cys
      20

```

(2) INFORMATION FOR SEQ ID NO:6:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY:

35

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- 30 -

(A) NAME/KEY:

(B) OTHER INFORMATION: The lysine residue at position 8 has a peptide bond between the carboxyl group of Acp and the  $\alpha$  amino group of the lysine, and the  $\epsilon$  amino group of the lysine at position 8 forms a peptide bond with the carboxyl group of the cysteine residue at position 9 and the amino acid residues at positions 9-21 are preferably D-amino acid residues;

10            Glu Asp Val Val Cys Cys AcP Lys Cys Val Val Ile Val Gly Arg  
                       5                                 10                                 15  
Ile Val Leu Ser Gly Lys  
                               20

(2) INFORMATION FOR SEQ ID NO:7:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

20

(D) TOPOLOGY:

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

25

(A) NAME/KEY:

(B) OTHER INFORMATION: Amino acids at positions 8-20 are preferably D-amino acids.

Glu Asp Val Val Cys Cys AcP Lys Gly Ser Leu Val Ile Arg Gly  
30                   5                         10                         15  
Val Ile Val Val Cys Lys  
                    20

(2) INFORMATION FOR SEQ ID NO:8:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid



- 31 -

(C) STRANDEDNESS:

(D) TOPOLOGY:

(ii) MOLECULE TYPE: peptide

5

(ix) FEATURE:

(A) NAME/KEY:

(B) OTHER INFORMATION:

Xaa is a lysine wherein the  $\epsilon$  amino group of which forms a peptide bond with the carboxyl group of the cysteine residue at position 8 and the carboxyl group of the lysine residue forms a peptide bond with an  $\alpha$  amino group of another lysine residue (not shown), preferably the amino acid residues at positions 8 - 20 are D- amino acid residues.

15      Glu Asp Val Val Cys Cys Xaa Cys Val Val Ile Val Gly Arg Ile  
                                5                         10                         15

Val Leu Ser Gly Lys.  
                                20

20 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids

(B) TYPE: amino acid

25 (C) STRANDEDNESS:

(D) TOPOLOGY:

(ii) MOLECULE TYPE: peptide

30 (ix) FEATURE:

(A) NAME/KEY:

(B) OTHER INFORMATION: The amino acid residues at positions 1- 13 are preferably D-amino acid residues and lysine at position 14 is preferably an L-amino acid residue;

35

Lys Gly Ser Leu Val Ile Arg Gly Val Ile Val Val Cys Lys  
5 10

- 32 -

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

5 (B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY:

## (ii) MOLECULE TYPE: peptide

10

## (ix) FEATURE:

(A) NAME/KEY:

(B) OTHER INFORMATION: Amino acid residues at positions 1 -  
11 are preferably D-amino acids;

15

Lys Gly Ser Leu Val Ile Arg Gly Val Ile Val Lys

5

10

## INFORMATION FOR SEQ ID NO:11:

20

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

25 (D) TOPOLOGY:

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

30 (A) NAME/KEY:

(B) OTHER INFORMATION: The amino acid residues are  
preferably D-amino acid residues.

Cys Val Val Ile Val Gly Arg Ile Val Leu Ser Gly

35

5

10

## INFORMATION FOR SEQ ID NO:12:

- 33 -

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

5 (D) TOPOLOGY:

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

10 (A) NAME/KEY:

(B) OTHER INFORMATION: The amino acid residues are preferably D-amino acids and the serine residue at position 1 is preferably acetylated;

15 Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val

5

## INFORMATION FOR SEQ ID NO:13:

## 20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY:

25

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

(A) NAME/KEY:

30 (B) OTHER INFORMATION: The amino acid residues are preferably D-amino acid residues and the lysine residue at position 1 is preferably acetylated.

Lys Gly Ser Leu Val Ile Arg Gly Val Ile Val Val Cys

35

5

10

## INFORMATION FOR SEQ ID NO:14:

- 34 -

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

5 (D) TOPOLOGY:

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

10 (A) NAME/KEY:

(B) OTHER INFORMATION: Xaa is biotin and the amino acid residues at positions 2 - 14 are preferably D-amino acids;

Xaa Lys Gly Ser Leu Val Ile Arg Gly Val Ile Val Val Cys Lys

15

5

10

Lys

## INFORMATION FOR SEQ ID NO:15:

## 20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY:

25

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

(A) NAME/KEY:

30 (B) OTHER INFORMATION: Xaa is a lysine residue in which the ε amino group of the lysine forms a peptide bond with a biotin and amino acid residues at positions 1 - 13 are preferably D-amino acid residues.

Lys Gly Ser Leu Val Ile Arg Gly Val Ile Val Val Cys Xaa Lys

35

5

10

15

## (2) INFORMATION FOR SEQ ID NO:16:

- 35 -

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 549 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

5

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

10

- (A) NAME/KEY: HCV NS3 Protease

GCG CCC ATC ACG GCG TAC GCC CAG CAG ACG AGA GGC CTC CTA GGG 45  
 Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu Gly  
 1 5 10 15

15 TGT ATA ATC ACC AGC CTG ACT GGC CGG GAC AAA AAC CAA GTG GAG 90  
 Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu  
 20 25 30

20 GGT GAG GTC CAG ATC GTG TCA ACT GCT ACC CAA ACC TTC CTG GCA 135  
 Gly Glu Val Gln Ile Val Ser Thr Ala Thr Gln Thr Phe Leu Ala  
 35 40 45

25 ACG TGC ATC AAT GGG GTA TGC TGG ACT GTC TAC CAC GGG GCC GGA 180  
 Thr Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly  
 50 55 60

30 ACG AGG ACC ATC GCA TCA CCC AAG GGT CCT GTC ATC CAG ATG TAT 225  
 Thr Arg Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met Tyr  
 65 70 75

35 ACC AAT GTG GAC CAA GAC CTT GTG GGC TGG CCC GCT CCT CAA GGT 270  
 Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln Gly  
 80 85 90

TCC CGC TCA TTG ACA CCC TGC ACC TGC GGC TCC TCG GAC CTT TAC 315  
 Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr

- 36 -

|    |   |     |     |
|----|---|-----|-----|
|    | 95  | 100 | 105 |
|    | CTG GTT ACG AGG CAC GCC GAC GTC ATT CCC GTG CGC CGG CGA GGT 360 |     |     |
|    | Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly     |     |     |
| 5  | 110   | 115 | 120 |
|    | GAT AGC AGG GGT AGC CTG CTT TCG CCC CGG CCC ATT TCC TAC CTA 405 |     |     |
|    | Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu     |     |     |
|    | 125   | 130 | 135 |
| 10 | AAA GGC TCC TCG GGG GGT CCG CTG TTG TGC CCC GCG GGA CAC GCC 450 |     |     |
|    | Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala     |     |     |
|    | 140   | 145 | 150 |
| 15 | GTG GGC CTA TTC AGG GCC GCG GTG TGC ACC CGT GGA GTG ACC AAG 495 |     |     |
|    | Val Gly Leu Phe Arg Ala Ala Val Cys Thr Arg Gly Val Thr Lys     |     |     |
|    | 155   | 160 | 165 |
|    | GCG GTG GAC TTT ATC CCT GTG GAG AAC CTA GAG ACA ACC ATG AGA 540 |     |     |
| 20 | Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg     |     |     |
|    | 170   | 175 | 180 |
|    | TCC CCG GTG   |     |     |
|    | Ser Pro Val   |     |     |

25

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 162 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: NS4A

- 37 -

AGC ACC TGG GTG CTC GTT GGC GGC GTC CTG GCT GCT CTG GCC GCG 45  
 Ser Thr Trp Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala  
 1 5 10 15  
 5 TAT TGC CTG TCA ACA GGC TGC GTG GTC ATA GTG GGC AGG ATT GTC 90  
 Tyr Cys Leu Ser Thr Gly Cys Val Val Ile Val Gly Arg Ile Val  
 20 25 30  
 TTG TCC GGG AAG CCG GCA ATT ATA CCT GAC AGG GAG GTT CTC TAC 135  
 10 Leu Ser Gly Lys Pro Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr  
 35 40 45  
 CAG GAG TTC GAT GAG ATG GAA GAG TGC 162  
 Gln Glu Phe Asp Glu Met Glu Glu Cys  
 15 50

## (2) INFORMATION FOR SEQ ID NO:18:

- 20 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: double

- 25 (ii) MOLECULE TYPE: cDNA

GA TCA CCG GTC TAG ATCT  
 T GGC CAG ATC TAGA

## 30 (2) INFORMATION FOR SEQ ID NO:19:

- 35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 28 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- 38 -

(ix) FEATURE:

(A) NAME/KEY:

5    CCG   GTC   CGG   AAG   AAA   AAG   AGA   CGC   TAG   C  
     AG   GCC   TTC   TTT   TTC   TCT   GCG   ATC   G

(2) INFORMATION FOR SEQ ID NO:20:

10    (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 79 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY:

20    CCG   GCA   ATT   ATA   CCT   GAC   AGG   GAG   GTT   CTC   TAC   CAG   GAA   TTC  
     GT   TAA   TAT   GGA   CTG   TCC   CTC   CAA   GAG   ATG   GTC   CTT   AAG

GAT   GAG   ATG   GAA   GAG   TGC   CGG   AAG   AAA   AAG   AGA   CGC   A  
CTA   CTC   TAC   CTT   CTC   ACG   GCC   TTC   TTT   TTC   TCT   GCG   TTC   GA

25

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

30    (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: polypeptide

35

(ix) FEATURE:

(A) NAME/KEY: NS4A Active Mutant



- 39 -

Cys Val Val Ile Val Gly Arg Ile Val Leu Ser Gly Lys  
5 10

## (2) INFORMATION FOR SEQ ID NO:22:

5

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: polypeptide

## (ix) FEATURE:

15 (A) NAME/KEY: Soluble 5A/5B Substrate

Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Thr Trp Thr  
5 10 15

Gly Lys

20

## (2) INFORMATION FOR SEQ ID NO:23:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 810 base pairs

25 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30

## (ix) FEATURE:

(A) NAME/KEY: pNB182Δ4AHT

35 ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC ACG GAT CCG CCC ATC 45  
Met Arg Gly Ser His His His His His His Thr Asp Pro Pro Ile  
1 5 10 15

- 40 -

|    |   |     |
|----|---|-----|
|    | ACG GCG TAC GCC CAG CAG ACG AGA GGC CTC CTA GGG TGT ATA ATC | 90  |
|    | Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile Ile |     |
|    | 20 25 30  |     |
| 5  | ACC AGC CTG ACT GGC CGG GAC AAA AAC CAA GTG GAG GGT GAG GTC | 135 |
|    | Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val |     |
|    | 35 40 45  |     |
|    | CAG ATC GTG TCA ACT GCT ACC CAA ACC TTC CTG GCA ACG TGC ATC | 180 |
| 10 | Gln Ile Val Ser Thr Ala Thr Gln Thr Phe Leu Ala Thr Cys Ile |     |
|    | 50 55 60  |     |
|    | AAT GGG GTA TGC TGG ACT GTC TAC CAC GGG GCC GGA ACG AGG ACC | 225 |
| 15 | Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr |     |
|    | 65 70 75  |     |
|    | ATC GCA TCA CCC AAG GGT CCT GTC ATC CAG ATG TAT ACC AAT GTG | 270 |
|    | Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met Tyr Thr Asn Val |     |
| 20 | 80 85 90  |     |
|    | GAC CAA GAC CTT GTG GGC TGG CCC GCT CCT CAA GGT TCC CGC TCA | 315 |
|    | Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln Gly Ser Arg Ser |     |
| 25 | 95 100 105  |     |
|    | TTG ACA CCC TGC ACC TGC GGC TCC TCG GAC CTT TAC CTG GTT ACG | 360 |
|    | Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr |     |
| 30 | 110 115 120   |     |
|    | AGG CAC GCC GAC GTC ATT CCC GTG CGC CGG CGA GGT GAT AGC AGG | 405 |
|    | Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg |     |
| 35 | 125 130 135   |     |

- 41 -

GGT AGC CTG CTT TCG CCC CGG CCC ATT TCC TAC CTA AAA GGC TCC 450  
 Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser  
 140 145 150

5 TCG GGG GGT CCG CTG TTG TGC CCC GCG GGA CAC GCC GTG GGC CTA 495  
 Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Leu  
 155 160 165

TTC AGG GCC GCG GTG TGC ACC CGT GGA GTG ACC AAG GCG GTG GAC 540  
 10 Phe Arg Ala Ala Val Cys Thr Arg Gly Val Thr Lys Ala Val Asp  
 170 175 180

TTT ATC CCT GTG GAG AAC CTA GAG ACA ACC ATG AGA TCC CCG GGG 585  
 Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Gly  
 15 185 190 195

GTG CTC GTT GGC GGC GTC CTG GCT GCT CTG GCC GCG TAT TGC CTG 630  
 Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu  
 200 205 210

20 TCA ACA GGC TGC GTG GTC ATA GTG GGC AGG ATT GTC TTG TCC GGG 720  
 Ser Thr Gly Cys Val Val Ile Val Gly Arg Ile Val Leu Ser Gly  
 215 220 225

AAG CCG GCA ATT ATA CCT GAC AGG GAG GTT CTC TAC CAG GAG TTC 765  
 25 Lys Pro Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr Gln Glu Phe  
 230 235 240

GAT GAG ATG GAA GAG TGC CGG AAG AAA AAG AGA CGC AAG CTT AAT 810  
 30 Asp Glu Met Glu Glu Cys Arg Lys Lys Lys Arg Arg Lys Leu Asn  
 245 250 255

## (2) INFORMATION FOR SEQ ID NO:24:

- 35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 162 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single

- 42 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5 (ix) FEATURE:

(A) NAME/KEY: Native NS4A

TCA ACA TGG GTG CTC GTT GGC GGC GTC CTG GCT GCT CTG GCC GCG 45  
 Ser Thr Trp Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala  
 10 1 5 10 15  
  
 TAT TGC CTG TCA ACA GGC TGC GTG GTC ATA GTG GGC AGG ATT GTC 90  
 Tyr Cys Leu Ser Thr Gly Cys Val Val Ile Val Gly Arg Ile Val  
 20 25 30  
 15  
 TTG TCC GGG AAG CCG GCA ATT ATA CCT GAC AGG GAG GTT CTC TAC 135  
 Leu Ser Gly Lys Pro Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr  
 35 40 45  
 20 CAG GAG TTC GAT GAG ATG GAA GAG TGC  
 Gln Glu Phe Asp Glu Met Glu Glu Cys  
 50

2) INFORMATION FOR SEQ ID NO:25:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: polypeptide

(ix) FEATURE:

35

(A) NAME/KEY: Native 5A/5B Substrate

- 43 -

Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Thr Trp Thr  
5 10 15  
Gly

5 2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

10 (C) STRANDEDNESS:

(D) TOPOLOGY:

## (ii) MOLECULE TYPE: polypeptide

15 (ix) FEATURE:

(A) NAME/KEY: NS3/NS4A Cleavage site

Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu  
5 10 15  
Val Gly Gly Val Leu  
20

2) INFORMATION FOR SEQ ID NO:27:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: polypeptide

(ix) **FEATURE:**

(A) NAME/KEY: NS4A/4B Cleavage Site

35 Tyr Gln Glu Phe Asp Glu Met Glu Glu Cys Ser Gln His Leu Pro  
5 10 15  
Tyr Ile Glu Gln Gly  
20

- 44 -

## 2) INFORMATION FOR SEQ ID NO:28:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 10 (ii) MOLECULE TYPE: polypeptide

## (ix) FEATURE:

- (A) NAME/KEY: 4B/5A

15 Trp Ile Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu  
5 10 15  
Arg Asp Ile Trp Asp  
20

## 20 2) INFORMATION FOR SEQ ID NO:29:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
25 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: polypeptide

## 30 (ix) FEATURE:

- (A) NAME/KEY:

Glu-Asp-Val-Val-Cys-Cys-Acp-Lys  
5

35

## 2) INFORMATION FOR SEQ ID NO:30:

## (i) SEQUENCE CHARACTERISTICS:

- 45 -

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: polypeptide

(ix) FEATURE:

(A) NAME/KEY:

10

Cys-Val-Val-Ile-Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys

5

10

- 46 -

WE CLAIM:

1. A bivalent inhibitor of an hepatitis C NS3 protease comprised of a  
5 first peptide linked to a second peptide, said first peptide being a  
subsequence, a mutated subsequence or a mutated full-length sequence  
of a substrate of the hepatitis C NS3 protease and said second peptide  
being a subsequence of a hepatitis C NS4A polypeptide.
- 10 2. The bivalent inhibitor of claim 1 selected from the group consisting  
of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4,  
SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
3. An inhibitor of an HCV protease comprised of a peptide, said peptide  
15 being a subsequence, a mutated subsequence or a mutated full-length  
sequence of a substrate of the HCV NS3 protease.
4. An inhibitor of claim 3 selected from the group consisting of SEQ ID  
NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13,  
20 SEQ ID NO: 14 and SEQ ID NO: 15.
5. An inhibitor of an HCV NS3 protease comprised of a peptide, said  
peptide being a subsequence, a mutated subsequence or a mutated full-  
length sequence of an HCV NS4A polypeptide.  
25
6. The use of an inhibitor of an HCV NS3 protease for the manufacture  
of a medicament for treating hepatitis C, wherein the inhibitor is  
comprised of a first peptide linked to a second peptide, said first peptide  
being a subsequence, mutated subsequence or a mutated full-length  
30 sequence of a substrate of the hepatitis C NS3 protease and said second  
peptide being a subsequence, a mutated subsequence or a mutated full-  
length sequence of a hepatitis C NS4A polypeptide.
7. The use of claim 6 wherein the inhibitor is selected from the group  
35 consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4,  
SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.



- 47 -

8. The use of an inhibitor of an HCV NS3 protease for the manufacture of a medicament for treating hepatitis C, wherein the inhibitor is comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.
9. The use of claim 8 wherein the inhibitor is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.
10. The use of an inhibitor of an HCV NS3 protease for the manufacture of a medicament for treating hepatitis C, wherein the inhibitor is comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length subsequence of an HCV NS4A polypeptide.
11. A pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being an inhibitor of an HCV NS3 protease, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide, and a pharmaceutical carrier.
12. The pharmaceutical composition of claim 11 wherein the inhibitor is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
13. A pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, said inhibitor being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.

- 48 -

14. The pharmaceutical composition of claim 13 wherein the inhibitor is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.

5

15. A pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, wherein said inhibitor is comprised of a peptide, said peptide  
10 being a subsequence, a mutated subsequence or a mutated full-length subsequence of an HCV NS4A polypeptide.

15

Figure 1




FIGURE 2

2) Construction of the plasmid pBJ1015 (Expressing NS3 in E. coli)




FIGURE 3

8) Construction of the plasmid pT556-9 (With a stop codon after aa 183)




FIGURE 4

III) Construction of the plasmid pJ7B1006 (Fused with a string of positively charged aa at the carboxy end of NS3 183)





FIGURE 5

iv) Construction of the plasmid pBJ1022 [expressing His-NS3(182)-HT in E.coli]



**FIGURE 6**

v) Construction of the plasmid pNB(-V)182-64A HT







FIGURE 7

## Construction of pTS HIs/HIV/NS3(183)



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/07632

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07K14/18 C07K19/00 A61K39/29

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| A          | WO 95 22985 A (ISTITUTO DI RICERCHE DI BIOLOG ;FRANCESCO RAFFAELE DE (IT); FAILLA) 31 August 1995<br>see page 3, last paragraph - page 4, paragraph 3; example 4<br>---  | 1-15                  |
| A          | HIROAKI OKAMOTO ET AL.: "The 5'-terminal sequence of the Hepatitis C Virus genome " THE JAPANESE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 60, no. 1, January 1990, pages 167-177, XP002042711<br>see the whole document<br>---<br>-/-- | 1-15                  |

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 October 1997

Date of mailing of the international search report

28.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/07632

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| P,X        | <p>WO 96 36702 A (SCHERING CORPORATION) 21<br/> November 1996<br/> see page 3, line 15 - line 19<br/> see page 6, line 12 - line 20<br/> see page 13, line 27 - page 14, line 10;<br/> example 3</p> <p>---</p> | 1,3,6,8,<br>11,13     |
| P,X        | <p>WO 96 35806 A (SCHERING CORPORATION) 14<br/> November 1996<br/> see page 6, line 35 - page 7, line 1;<br/> example 5</p> <p>---</p>  | 3,8,13                |
| P,X        | <p>WO 96 35717 A (SCHERING CORPORATION) 14<br/> November 1996<br/> see page 4, line 10 - line 37<br/> see page 13, line 15 - line 37; example 3</p> <p>-----</p>  | 3,8,13                |

# INTERNATIONAL SEARCH REPORT

International Publication No

PCT/US 97/07632

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9522985 A                              | 31-08-95            | AU 1822395 A               | 11-09-95            |
|   |                     | CA 2182521 A               | 31-08-95            |
|   |                     | EP 0746333 A               | 11-12-96            |
| -----                                     | -----               | -----                      | -----               |
| WO 9636702 A                              | 21-11-96            | AU 5729196 A               | 29-11-96            |
| -----                                     | -----               | -----                      | -----               |
| WO 9635806 A                              | 14-11-96            | AU 5729096 A               | 29-11-96            |
| -----                                     | -----               | -----                      | -----               |
| WO 9635717 A                              | 14-11-96            | AU 5729296 A               | 29-11-96            |
| -----                                     | -----               | -----                      | -----               |